B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome

Abstract EN

Antibody-mediated rejection (ABMR) of renal allograft lacks typical phenotypes and clinical manifestations, always resulting in delayed diagnosis and treatment.

It has been considered to be an elemental factor influencing the improvement of the long-term outcome of renal allograft.

The B cell activating factor (BAFF) signal plays a fundamental function in the process of antibody-mediated immune response.

Data from recipients and the nonhuman primate ABMR model suggest that the BAFF signal participates in the ABMR of renal allograft, while there are objections.

The challenges in the diagnosis of ABMR, different study population, and details of research may explain the discrepancy.

Large quantities of dynamic, credible data of BAFF ligands and their association with renal allograft pathological characteristics would constitute a direct proof of the role of BAFF in the progression of renal allograft ABMR.